RU2374228C2 - Производные 4-фенилпиперидина в качестве ингибиторов ренина - Google Patents
Производные 4-фенилпиперидина в качестве ингибиторов ренина Download PDFInfo
- Publication number
- RU2374228C2 RU2374228C2 RU2006122637/04A RU2006122637A RU2374228C2 RU 2374228 C2 RU2374228 C2 RU 2374228C2 RU 2006122637/04 A RU2006122637/04 A RU 2006122637/04A RU 2006122637 A RU2006122637 A RU 2006122637A RU 2374228 C2 RU2374228 C2 RU 2374228C2
- Authority
- RU
- Russia
- Prior art keywords
- hydrogen
- aryl
- represents hydrogen
- pharmaceutically acceptable
- compound according
- Prior art date
Links
- UTBULQCHEUWJNV-UHFFFAOYSA-N 4-phenylpiperidine Chemical class C1CNCCC1C1=CC=CC=C1 UTBULQCHEUWJNV-UHFFFAOYSA-N 0.000 title 1
- 239000002461 renin inhibitor Substances 0.000 title 1
- 229940086526 renin-inhibitors Drugs 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 46
- 239000001257 hydrogen Substances 0.000 claims abstract 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 34
- 150000001875 compounds Chemical class 0.000 claims abstract 21
- 125000003118 aryl group Chemical group 0.000 claims abstract 19
- 150000003839 salts Chemical class 0.000 claims abstract 15
- 125000000217 alkyl group Chemical group 0.000 claims abstract 11
- 108090000783 Renin Proteins 0.000 claims abstract 9
- 102100028255 Renin Human genes 0.000 claims abstract 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract 9
- 229910052736 halogen Inorganic materials 0.000 claims abstract 9
- 150000002367 halogens Chemical class 0.000 claims abstract 9
- 150000002431 hydrogen Chemical class 0.000 claims abstract 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 7
- 230000000694 effects Effects 0.000 claims abstract 6
- 125000002541 furyl group Chemical group 0.000 claims abstract 6
- 125000001041 indolyl group Chemical group 0.000 claims abstract 6
- 125000004076 pyridyl group Chemical group 0.000 claims abstract 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract 6
- 125000001544 thienyl group Chemical group 0.000 claims abstract 6
- 125000002947 alkylene group Chemical group 0.000 claims abstract 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract 5
- 125000004429 atom Chemical group 0.000 claims abstract 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 4
- 241000124008 Mammalia Species 0.000 claims abstract 3
- 125000004442 acylamino group Chemical group 0.000 claims abstract 2
- 125000004423 acyloxy group Chemical group 0.000 claims abstract 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims abstract 2
- 125000003282 alkyl amino group Chemical group 0.000 claims abstract 2
- -1 alkyloxyalkoxy Chemical group 0.000 claims abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract 2
- 125000001589 carboacyl group Chemical group 0.000 claims abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims abstract 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 5
- 208000010877 cognitive disease Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000009787 cardiac fibrosis Effects 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 230000006444 vascular growth Effects 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 206010051602 Laziness Diseases 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004410 intraocular pressure Effects 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 108090000746 Chymosin Proteins 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/42—Oxygen atoms attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52537503P | 2003-11-26 | 2003-11-26 | |
| US60/525,375 | 2003-11-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006122637A RU2006122637A (ru) | 2008-01-27 |
| RU2374228C2 true RU2374228C2 (ru) | 2009-11-27 |
Family
ID=34632979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006122637/04A RU2374228C2 (ru) | 2003-11-26 | 2004-11-25 | Производные 4-фенилпиперидина в качестве ингибиторов ренина |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20070078164A1 (enExample) |
| EP (1) | EP1689712B1 (enExample) |
| JP (1) | JP4750712B2 (enExample) |
| KR (1) | KR20060120146A (enExample) |
| CN (1) | CN1906163A (enExample) |
| AT (1) | ATE440082T1 (enExample) |
| AU (1) | AU2004293177B2 (enExample) |
| BR (1) | BRPI0416976A (enExample) |
| CA (1) | CA2546264A1 (enExample) |
| DE (1) | DE602004022704D1 (enExample) |
| ES (1) | ES2332053T3 (enExample) |
| PL (1) | PL1689712T3 (enExample) |
| PT (1) | PT1689712E (enExample) |
| RU (1) | RU2374228C2 (enExample) |
| WO (1) | WO2005051911A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0416976A (pt) * | 2003-11-26 | 2007-02-21 | Novartis Ag | derivados de 4-fenilpiperidina como inibidores de renina |
| AU2005276624B2 (en) | 2004-08-25 | 2011-09-29 | Actelion Pharmaceuticals Ltd. | Bicyclononene derivatives as renin inhibitors |
| EP2248520A3 (en) * | 2004-10-08 | 2010-11-17 | Novartis AG | Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure |
| GB0428526D0 (en) | 2004-12-30 | 2005-02-09 | Novartis Ag | Organic compounds |
| EP1707202A1 (de) * | 2005-03-31 | 2006-10-04 | Speedel Experimenta AG | Organische Verbindungen |
| GB0508992D0 (en) * | 2005-05-03 | 2005-06-08 | Novartis Ag | Organic compounds |
| US7799805B2 (en) | 2005-05-27 | 2010-09-21 | Actelion Pharmaceuticals Ltd. | Piperidine carboxylic acid amide derivatives |
| GB0514203D0 (en) * | 2005-07-11 | 2005-08-17 | Novartis Ag | Organic compounds |
| NZ569135A (en) | 2005-12-30 | 2011-08-26 | Novartis Ag | 3,5-Substituted piperidine compounds as renin inhibitors |
| RU2415840C2 (ru) * | 2005-12-30 | 2011-04-10 | Новартис Аг | 3,5-замещенные пиперидины, как ингибиторы ренина |
| GB0611696D0 (en) * | 2006-06-13 | 2006-07-26 | Novartis Ag | Organic compounds |
| TW200821303A (en) * | 2006-08-08 | 2008-05-16 | Speedel Experimenta Ag | Organic compounds |
| WO2008074450A2 (en) * | 2006-12-20 | 2008-06-26 | Nicox S.A. | Non-peptidic renin inhibitors nitroderivatives |
| EP1987834A3 (en) * | 2007-02-13 | 2008-11-19 | Speedel Experimenta AG | Substituted piperidines as therapeutic compounds |
| EP1958634A3 (en) * | 2007-02-14 | 2008-09-24 | Speedel Experimenta AG | Substituted piperidines as inhibitors of beta-secretase, cathepsin D, plasmepsin II and/or HIV protease |
| WO2009000811A1 (en) | 2007-06-25 | 2008-12-31 | Novartis Ag | N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU98106388A (ru) * | 1995-09-07 | 2000-02-20 | Ф.Хоффманн-Ля Рош Аг | Новые 4-(оксиалкоксифенил)-3-оксипиперидины для лечения сердечной и почечной недостаточности |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4616088A (en) * | 1984-10-29 | 1986-10-07 | E. R. Squibb & Sons, Inc. | Amino acid ester and amide renin inhibitor |
| US5668151A (en) * | 1995-06-07 | 1997-09-16 | Bristol-Myers Squibb Company | Dihydropyridine NPY antagonists: piperidine derivatives |
| PL193686B1 (pl) * | 1995-09-07 | 2007-03-30 | Hoffmann La Roche | Pochodne piperydyny, środki lecznicze zawierającepochodne piperydyny, sposoby wytwarzania tych pochodnych oraz zastosowanie pochodnych |
| AU3818900A (en) | 1999-04-14 | 2000-11-02 | F. Hoffmann-La Roche Ag | Process for the preparation of substituted piperidines |
| US6376672B1 (en) | 1999-04-27 | 2002-04-23 | Hoffmann-La Roche Inc. | Naphthalenylmethoxypiperidines as renin inhibitors |
| US6197959B1 (en) | 1999-04-27 | 2001-03-06 | Hoffmann-La Roche Inc. | Piperidine derivatives |
| US20060079533A1 (en) | 2001-03-23 | 2006-04-13 | Nieman James A | Methods of treating alzheimer's disease |
| AU2002256418A1 (en) | 2001-04-27 | 2002-11-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of bace |
| WO2004002549A1 (en) * | 2002-06-28 | 2004-01-08 | Novartis Ag | Use of organic compounds |
| US20040214832A1 (en) | 2003-04-10 | 2004-10-28 | Cuiman Cai | Piperazine derivative renin inhibitors |
| US20040204455A1 (en) | 2003-04-10 | 2004-10-14 | Cody Wayne Livingston | Piperidine derivative rennin inhibitors |
| BRPI0416976A (pt) * | 2003-11-26 | 2007-02-21 | Novartis Ag | derivados de 4-fenilpiperidina como inibidores de renina |
-
2004
- 2004-11-25 BR BRPI0416976-0A patent/BRPI0416976A/pt not_active IP Right Cessation
- 2004-11-25 KR KR1020067010229A patent/KR20060120146A/ko not_active Ceased
- 2004-11-25 PL PL04798086T patent/PL1689712T3/pl unknown
- 2004-11-25 DE DE602004022704T patent/DE602004022704D1/de not_active Expired - Lifetime
- 2004-11-25 JP JP2006540386A patent/JP4750712B2/ja not_active Expired - Fee Related
- 2004-11-25 AU AU2004293177A patent/AU2004293177B2/en not_active Ceased
- 2004-11-25 EP EP04798086A patent/EP1689712B1/en not_active Expired - Lifetime
- 2004-11-25 WO PCT/EP2004/013410 patent/WO2005051911A1/en not_active Ceased
- 2004-11-25 CN CNA2004800409431A patent/CN1906163A/zh active Pending
- 2004-11-25 US US10/580,296 patent/US20070078164A1/en not_active Abandoned
- 2004-11-25 PT PT04798086T patent/PT1689712E/pt unknown
- 2004-11-25 RU RU2006122637/04A patent/RU2374228C2/ru not_active IP Right Cessation
- 2004-11-25 ES ES04798086T patent/ES2332053T3/es not_active Expired - Lifetime
- 2004-11-25 AT AT04798086T patent/ATE440082T1/de not_active IP Right Cessation
- 2004-11-25 CA CA002546264A patent/CA2546264A1/en not_active Abandoned
-
2008
- 2008-06-27 US US12/163,038 patent/US7754727B2/en not_active Expired - Fee Related
-
2010
- 2010-05-28 US US12/789,892 patent/US8362040B2/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU98106388A (ru) * | 1995-09-07 | 2000-02-20 | Ф.Хоффманн-Ля Рош Аг | Новые 4-(оксиалкоксифенил)-3-оксипиперидины для лечения сердечной и почечной недостаточности |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1689712A1 (en) | 2006-08-16 |
| JP4750712B2 (ja) | 2011-08-17 |
| BRPI0416976A (pt) | 2007-02-21 |
| CA2546264A1 (en) | 2005-06-09 |
| EP1689712B1 (en) | 2009-08-19 |
| KR20060120146A (ko) | 2006-11-24 |
| RU2006122637A (ru) | 2008-01-27 |
| DE602004022704D1 (de) | 2009-10-01 |
| AU2004293177A1 (en) | 2005-06-09 |
| US20070078164A1 (en) | 2007-04-05 |
| PL1689712T3 (pl) | 2010-01-29 |
| US7754727B2 (en) | 2010-07-13 |
| US20080269255A1 (en) | 2008-10-30 |
| JP2007512282A (ja) | 2007-05-17 |
| ES2332053T3 (es) | 2010-01-25 |
| US20100240679A1 (en) | 2010-09-23 |
| US8362040B2 (en) | 2013-01-29 |
| AU2004293177B2 (en) | 2008-10-23 |
| WO2005051911A1 (en) | 2005-06-09 |
| ATE440082T1 (de) | 2009-09-15 |
| PT1689712E (pt) | 2009-11-25 |
| CN1906163A (zh) | 2007-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2324684C2 (ru) | Пиримидиновые производные | |
| WO2005051895A8 (en) | Organic compounds | |
| US7375136B2 (en) | pH-dependent NMDA receptor antagonists | |
| Sunkel et al. | Synthesis of 3-[(2, 3-dihydro-1, 1, 3-trioxo-1, 2-benzisothiazol-2-yl) alkyl] 1, 4-dihydropyridine-3, 5-dicarboxylate derivatives as calcium channel modulators | |
| HUP9901478A2 (hu) | Karbolinszármazékok, előállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények | |
| US20070093492A1 (en) | Pyrrolidine derivatives | |
| EP2919779B1 (en) | Cannabinoid receptor mediating compounds | |
| CA2370888A1 (en) | Renin inhibitors | |
| JP2550455B2 (ja) | ４ーアルキルイミダゾール誘導体 | |
| CA2681972A1 (en) | Substituted dibenzoic acid derivatives and use thereof | |
| CA2370244A1 (en) | Piperidine derivatives | |
| CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity | |
| EP3303325A1 (en) | Cannabinoid receptor mediating compounds | |
| RU2006122637A (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| CA2626464A1 (en) | Tetrazol derivatives and their use for the treatment of cardiovascular diseases | |
| JP2007506692A5 (enExample) | ||
| WO1997032863A1 (en) | Thiazolidine-2,4-dione derivatives | |
| AU658266B2 (en) | 4-amino-2-ureidopyrimidine-5-carboxamides, a process for the preparation thereof, pharmaceuticals containing these compounds, and the use thereof | |
| WO2004071428A3 (en) | 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | |
| EP1080081A1 (en) | Benzofuroxan derivatives and their use in treating angina pectoris | |
| WO2000015604A1 (fr) | Derives de diesters maloniques et leur procede d'obtention | |
| FR2577552A1 (fr) | Esters heterocycliques dissymetriques d'acides 1,4-dihydropyridine-3,5-dicarboxyliques, procede de preparation et utilisation en therapeutique | |
| PT78491B (en) | Process for the preparation of new 5-acyl-2-(1h)-pyridinones useful as cardiotonic agents | |
| CA2477720A1 (en) | Quinoline derivatives | |
| IE921771A1 (en) | New 2-amino-5-cyano-1,4-dihydropyridines, processes for¹their preparation and their use in medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20091126 |